Allergan introduces hybrid injectable
Global pharmaceutical company Allergan Aesthetics has launched HArmonyCa to the UK market, a hybrid injectable treatment combining hyaluronic acid (HA) and calcium hydroxyapatite (CaHA).
Global pharmaceutical company Allergan Aesthetics has launched HArmonyCa to the UK market, a hybrid injectable treatment combining hyaluronic acid (HA) and calcium hydroxyapatite (CaHA).
Oral and maxillofacial surgery registrar Mr James Olding has been appointed as an Allergan Faculty member.
The Royal College of Ophthalmology will host a seminar on bridging the gap between medical aesthetics and ophthalmology, facial aesthetics and oculoplastics, and aesthetic surgery and functional surgery.
Meet your potential – the evolution of body contouring
Global pharmaceutical company Allergan Aesthetics is hosting a free webinar to launch the new CoolSculpting Elite device.
Global pharmaceutical company Allergan Aesthetics, an AbbVie company, has entered into an exclusive development and commercialisation agreement with regenerative medicine company CollPlant to use its plant-derived recombinant human collagen.
Global pharmaceutical company Allergan Aesthetics is launchings its first body contouring system in more than 10 years.
According to a report published by Fortune Business Insights, the botulinum toxin market will reach US $8,309 million by 2026, exhibiting a compound annual growth rate of 8%.
Global pharmaceutical company Allergan Aesthetics has launched a new brand identity to empower confidence and promote diversity.
Global pharmaceutical company Allergan, an AbbVie company, has entered an agreement with privately owned aesthetics company Luminera.